BioSpace News Archive

Catalent, Inc. announced the promotion of Thomas Castellano to serve as the company’s Senior Vice President and Chief Financial Officer effective June 1, 2021, succeeding Wetteny Joseph who will be leaving the company to become the Chief Financial Officer of Zoetis Inc.

Transposon technology efficiently generates active CAR-NK cells and has potential advantages compared to viral approaches Oral presentation highlighted at the American Society of Gene and Cell Therapy annual meeting

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast on Wednesday, May 19, 2021 at 10:30 a.m.

As new trade routes begin to emerge and competition intensifies in the Arctic, Spire is providing data to inform decisions on critical issues around climate change, navigation, and transportation within the region through its comprehensive data and weather forecasting services.

TSHA-120 program demonstrated clear arrest of disease progression and long-term durability at therapeutic dose levels in patients with giant axonal neuropathy (GAN); Expects clinical data from highest dose cohort in second half of 2021 and regulatory feedback from agencies by year-end 2021 Expects to have five programs in Phase 1/2 trials in the second half of 2021, including GAN,

IMV continues to add industry expertise with appointment of Dr. Michael Kalos, an internationally recognized expert in T cell therapy and immunotherapy James Hall to retire at the AGM after 11 years as a board member

BLA submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant, expected in fourth quarter of 2021 Pre-commercial and manufacturing activities underway to support potential launch of omidubicel in 2022 Phase 1/2 clinical trial of allogeneic, off-the-shelf GDA-201 in NHL planned with IND submission anticipated in the second half of 2021

Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, announced today that it has received funding from the Crohn’s & Colitis Foundation’s IBD Ventures program to further develop Progenity’s first-in-class oral Drug Delivery System (DDS) for delivery of targeted therapeutics for inflammatory bowel disease (IBD).

Nuvo Pharmaceuticals ® Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Jesse Ledger , Miravo’s President & Chief Executive Officer will be presenting at the Q2 Virtual Investor Summit.

First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer